Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A phase II trial evaluating the efficacy of high‐dose Radioiodinated Tositumomab ( Anti‐CD20 ) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high‐risk relapsed or refractory non‐hodgkin lymphoma

Autor: Darrell R. Fisher, Damian J. Green, Victor A. Chow, Joseph G. Rajendran, John M. Pagel, Ted Gooley, Ryan D. Cassaday, Oliver W. Press, Frederick R. Appelbaum, Ajay K. Gopal, Leona Holmberg, Philip A. Stevenson, Paul S. Martin

Publikováno v: American Journal of Hematology. 95:775-783

Radiation is the most effective treatment for localized lymphoma, but treatment of multifocal disease is limited by toxicity. Radioimmunotherapy (RIT) delivers tumoricidal radiation to multifocal sites, further augmenting response by dose-escalation.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::823e791d64d23422d9285502e293e0bd
https://doi.org/10.1002/ajh.25818

Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts

Autor: Richard L. Wahl, Bernadette V. Marquez-Nostra, Jason T. Yoon, Mark S. Longtine

Publikováno v: Journal of Nuclear Medicine. 59:1219-1224

Radioimmunotherapies with monoclonal antibodies to the B-lymphocyte antigen 20 (CD20) are effective treatments for B-cell lymphomas, but U.S. Food and Drug Administration–approved radioimmunotherapies exclusively use radiolabeled murine antibodies,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c362205363db78021d3a1442c5e31ff
https://doi.org/10.2967/jnumed.117.203299

Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma

Autor: Jacene, Heather, Crandall, John, Kasamon, Yvette L, Ambinder, Richard F, Piantadosi, Steven, Serena, Donna, Kasecamp, Wayne, Wahl, Richard L

Publikováno v: Molecular imaging and biology, vol 19, iss 3
Jacene, H; Crandall, J; Kasamon, YL; Ambinder, RF; Piantadosi, S; Serena, D; et al.(2017). Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. Molecular Imaging and Biology, 19(3), 429-436. doi: 10.1007/s11307-016-1019-9. UCLA: Retrieved from: http://www.escholarship.org/uc/item/3fv9962m

PurposeTo determine the maximum tolerated dose (MTD) of [131I]tositumomab in patients with refractory/recurrent Hodgkin lymphoma (HL) and to preliminarily determine if [131I]tositumomab has activity against HL and if positron emission tomography (PET

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::79e5a8f601bfedcbb57c6260e8b8ef33
https://escholarship.org/uc/item/3fv9962m

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.